Skip Navigation

Cardiovascular Research 2000 47(2):329-335; doi:10.1016/S0008-6363(00)00106-1
© 2000 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Gray, D. F
Right arrow Articles by Rasmussen, H. H
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gray, D. F
Right arrow Articles by Rasmussen, H. H
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2000, European Society of Cardiology

HMG CoA reductase inhibition reduces sarcolemmal Na+–K+ pump density

David F Graya,b, Henning Bundgaardc, Peter S Hansena,b, Kerrie A Buhagiara,b, Anastasia S Mihailidoua, Wendy Jessupd, Keld Kjeldsenc and Helge H Rasmussena,b,*

aDepartment of Cardiology, Royal North Shore Hospital, Sydney, Australia
bThe University of Sydney, Sydney, Australia
cDepartment of Medicine, The Heart Centre, Rigshospitalet, National University Hospital, Copenhagen, Denmark
dThe Heart Research Institute, Sydney, Australia

* Corresponding author. Tel.: +61-2-9926-8680; fax: +61-2-9926-6521 helger{at}med.usyd.edu.au

Objectives: HMG CoA reductase inhibitors reduce cellular availability of mevalonate, a precursor in cholesterol synthesis. Since the cholesterol content of cell membranes is an important determinant of Na+–K+ pump function we speculated that treatment with HMG CoA reductase inhibitors affects Na+–K+ pump activity. Methods: We treated rabbits and rats for 2 weeks with the HMG CoA reductase inhibitor lovastatin and measured Na+–K+ pump current (Ip) in isolated rabbit cardiac myocytes using the whole cell patch-clamp technique, K-dependent p-nitrophenyl phosphatase (p-NPPase) activity in crude myocardial and skeletal muscle homogenates, and vanadate-facilitated 3H-ouabain binding in intact skeletal muscle samples from rats. Results: Treatment with lovastatin caused statistically significant reductions in Ip, myocardial and skeletal muscle K-dependent p-NPPase activity and 3H-ouabain binding in the myocardium and skeletal muscle. The lovastatin-induced decrease in Ip was eliminated by parenteral co-administration of mevalonate. However, this was not related to cardiac cholesterol content. Conclusions: Treatment with lovastatin reduces Na+–K+ pump activity and abundance in rabbit and rat sarcolemma.

KEYWORDS Cell culture/isolation; Cholesterol; Lipid metabolism; Membrane transport; Na/K-Pump


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
K. K. W. Chan, A. M. Oza, and L. L. Siu
The Statins as Anticancer Agents
Clin. Cancer Res., January 1, 2003; 9(1): 10 - 19.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
A. M Lefer, R. Scalia, and D. J Lefer
Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease
Cardiovasc Res, February 1, 2001; 49(2): 281 - 287.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.